Alzheimer disease

Disease-a-Month

Volumn 56, Issue 9, 2010, Pages 484-546

  Castellani, Rudy J ^a   Rolston, Raj K ^a   Smith, Mark A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANTIOXIDANT; ASCORBIC ACID; BAPINEUZUMAB; BETA SECRETASE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; ESTROGEN; GALANTAMINE; GAMMA SECRETASE; GLUTAMIC ACID; MEMANTINE; NAMANDA; NERVE GROWTH FACTOR; NEUROTROPIN; NONSTEROID ANTIINFLAMMATORY AGENT; PITTSBURGH COMPOUND B; RIVASTIGMINE; SELEGILINE; SEMAGACESTAT; STATIN; TARENFLURBIL; TAU PROTEIN; UNCLASSIFIED DRUG; 2-(4'-(METHYLAMINO)PHENYL)-6-HYDROXYBENZOTHIAZOLE; ANILINE DERIVATIVE; BIOLOGICAL MARKER; THIAZOLE DERIVATIVE;

ADENO ASSOCIATED VIRUS; ALZHEIMER DISEASE; BRAIN BLOOD FLOW; CHROMOSOME 1; CHROMOSOME 14; CHROMOSOME 19; CHROMOSOME 21; CLINICAL FEATURE; COGNITIVE DEFECT; DISEASE COURSE; DISEASE PREDISPOSITION; EDUCATIONAL STATUS; EXCITOTOXICITY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HEAD INJURY; HORMONE SUBSTITUTION; HUMAN; IMMUNIZATION; IMMUNOTHERAPY; INCIDENCE; NEUROFIBRILLARY TANGLE; NONHUMAN; PREVALENCE; REVIEW; SENESCENCE; SENILE DEMENTIA; SENILE PLAQUE; SEX RATIO; VASCULAR AMYLOIDOSIS; VIRAL GENE DELIVERY SYSTEM; AGE DISTRIBUTION; AGED; AMYLOID PLAQUE; BRAIN; CEREBRAL AMYLOID ANGIOPATHY; DEMENTIA; DIAGNOSTIC USE; DIFFERENTIAL DIAGNOSIS; ESTROGEN THERAPY; GENETICS; HEALTH; MEDITERRANEAN DIET; METABOLISM; MUTATION; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; RISK FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; ANTIOXIDANTS; BIOLOGICAL MARKERS; BRAIN; CEREBRAL AMYLOID ANGIOPATHY; CHOLINERGIC AGENTS; DEMENTIA; DIAGNOSIS, DIFFERENTIAL; DIET, MEDITERRANEAN; ESTROGEN REPLACEMENT THERAPY; GLOBAL HEALTH; HUMANS; IMMUNOTHERAPY; INCIDENCE; MUTATION; NERVE GROWTH FACTORS; NEUROFIBRILLARY TANGLES; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY; PREVALENCE; RISK FACTORS; TAU PROTEINS; THIAZOLES; TREATMENT OUTCOME;

EID: 77956470750     PISSN: 00115029     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.disamonth.2010.06.001     Document Type: Review

References (301)

1. Alzheimer A. Uber eine eigenartige Erkrankung der Hirnrinde. Allg Zeits Psychiatry PsychischYGerichtlich Med 1907, 64:146-148.
2. Roth M., Tomlinson B.E., Blessed G. Correlation between scores for dementia and counts of "senile plaques" in cerebral grey matter of elderly subjects. Nature 1966, 209:109-110.
3. Roth M., Tomlinson B.E., Blessed G. The relationship between quantitative measures of dementia and of degenerative changes in the cerebral grey matter of elderly subjects. Proc R Soc Med 1967, 60:254-260.
4. Tomlinson B.E., Blessed G., Roth M. Observations on the brains of demented old people. J Neurol Sci 1970, 11:205-242.
5. Berrios G. Alzheimer's disease: A conceptual history. Int J Geriatr Psychiatry 1990, 5:355-365.
6. Wiley C.A., Lopresti B.J., Venneti S., et al. Carbon 11-labeled Pittsburgh compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Arch Neurol 2009, 66:60-67.
7. Roe C.M., Mintun M.A., D'Angelo G., et al. Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh compound B uptake. Arch Neurol 2008, 65:1467-1471.
8. Klunk W.E. Biopsy support for the validity of Pittsburgh compound B positron emission tomography with a twist. Arch Neurol 2008, 65:1281-1283.
9. Cairns N.J., Ikonomovic M.D., Benzinger T., et al. Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol 2009, 66:1557-1562.
10. Aizenstein H.J., Nebes R.D., Saxton J.A., et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008, 65:1509-1517.
11. Leinonen V., Alafuzoff I., Aalto S., et al. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh compound B. Arch Neurol 2008, 65:1304-1309.
12. Petersen R.C. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004, 256:183-194.
13. Braak H., Rub U., Schultz C., et al. Vulnerability of cortical neurons to Alzheimer's and Parkinson's diseases. J Alzheimers Dis 2006, 9:35-44.
14. Fratiglioni L., De Ronchi D., Aguero-Torres H. Worldwide prevalence and incidence of dementia. Drugs Aging 1999, 15:365-375.
15. Small G.W., Rabins P.V., Barry P.P., et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 1997, 278:1363-1371.
16. Hebert L.E., Scherr P.A., Beckett L.A., et al. Age-specific incidence of Alzheimer's disease in a community population. JAMA 1995, 273:1354-1359.
17. Zhu C.W., Sano M. Economic considerations in the management of Alzheimer's disease. Clin Interv Aging 2006, 1:143-154.
18. Mirra S.S., Heyman A., McKeel D., et al. Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41:479-486. The Consortium to Establish a registry for Alzheimer's disease (CERAD).
19. Braak H., Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991, 82:239-259.
20. Lue L.F., Kuo Y.M., Roher A.E., et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 1999, 155:853-862.
21. Walsh D.M., Selkoe D.J. A beta oligomers-a decade of discovery. J Neurochem 2007, 101:1172-1184.
22. Castellani R.J., Lee H.G., Zhu X., et al. Alzheimer disease pathology as a host response. J Neuropathol Exp Neurol 2008, 67:523-531.
23. Nelson P.T., Braak H., Markesbery W.R. Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J Neuropathol Exp Neurol 2009, 68:1-14.
24. Brayne C., Richardson K., Matthews F.E., et al. Neuropathological correlates of dementia in over-80-year-old brain donors from the population-based Cambridge city over-75s cohort (CC75C) study. J Alzheimers Dis 2009, 18:645-658.
25. Prasher V.P., Farrer M.J., Kessling A.M., et al. Molecular mapping of Alzheimer-type dementia in Down's syndrome. Ann Neurol 1998, 43:380-383.
26. Brooks W.S., Kwok J.B., Kril J.J., et al. Alzheimer's disease with spastic paraparesis and "cotton wool" plaques: two pedigrees with PS-1 exon 9 deletions. Brain 2003, 126:783-791.
27. Janssen J.C., Lantos P.L., Fox N.C., et al. Autopsy-confirmed familial early-onset Alzheimer disease caused by the L15 3V presenilin 1 mutation. Arch Neurol 2001, 58:953-958.
28. Dickson D.W., Crystal H.A., Mattiace L.A., et al. Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol Aging 1992, 13:179-189.
29. Fischer O. Miliäre Nekrosen mit drusigen wucherungen der neurofibrillen, eine regelmässige veränderung der hirnrinde bei seniler demenz. Monatsschr Psychiatr Neurol 1907, 22:361-372.
30. Khachaturian Z.S. Diagnosis of Alzheimer's disease. Arch Neurol 1985, 42:1097-1105.
31. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's disease. Neurobiol Aging 1997, 18:S1-S2.
32. Terry R.D., Peck A., DeTeresa R., et al. Some morphometric aspects of the brain in senile dementia of the Alzheimer type. Ann Neurol 1981, 10:184-192.
33. Perry G., Castellani R.J., Smith M.A., et al. Oxidative damage in the olfactory system in Alzheimer's disease. Acta Neuropathol 2003, 106:552-556.
34. Whitwell J.L., Shiung M.M., Przybelski S.A., et al. MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment. Neurology 2008, 70:512-520.
35. Frisoni G.B., Lorenzi M., Caroli A., et al. In vivo mapping of amyloid toxicity in Alzheimer disease. Neurology 2009, 72:1504-1511.
36. Kromer Vogt L.J., Hyman B.T., Van Hoesen G.W., et al. Pathological alterations in the amygdala in Alzheimer's disease. Neuroscience 1990, 37:377-385.
37. Driscoll I., Resnick S.M., Troncoso J.C., et al. Impact of Alzheimer's pathology on cognitive trajectories in nondemented elderly. Ann Neurol 2006, 60:688-695.
38. Mahut H., Zola-Morgan S., Moss M. Hippocampal resections impair associative learning and recognition memory in the monkey. J Neurosci 1982, 2:1214-1220.
39. Zola-Morgan S., Squire L.R., Amaral D.G. Human amnesia and the medial temporal region: enduring memory impairment following a bilateral lesion limited to field CA1 of the hippocampus. J Neurosci 1986, 6:2950-2967.
40. Struble R.G., Price D.L., Cork L.C., et al. Senile plaques in cortex of aged normal monkeys. Brain Res 1985, 361:267-275.
41. Mann D.M., Esiri M.M. The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome. J Neurol Sci 1989, 89:169-179.
42. Hirano A., Zimmerman H.M. Silver impregnation of nerve cells and fibers in celloidin sections. A simple impregnation technique. Arch Neurol 1962, 6:114-122.
43. Ball M.J. Topographic distribution of neurofibrillary tangles and granulovacuolar degeneration in hippocampal cortex of aging and demented patients. A quantitative study. Acta Neuropathol 1978, 42:73-80.
44. Wilcock G.K., Esiri M.M. Plaques, tangles and dementia. A quantitative study. J Neurol Sci 1982, 56:343-356.
45. Hyman B.T., Van Hoesen G.W., Damasio A.R., et al. Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science 1984, 225:1168-1170.
46. Hyman B.T., Van Hoesen G.W., Kromer L.J., et al. Perforant pathway changes and the memory impairment of Alzheimer's disease. Ann Neurol 1986, 20:472-481.
47. Mann D.M., Yates P.O., Marcyniuk B. Dopaminergic neurotransmitter systems in Alzheimer's disease and in Down's syndrome at middle age. J Neurol Neurosurg Psychiatry 1987, 50:341-344.
48. Marcyniuk B., Mann D.M., Yates P.O. The topography of cell loss from locus caeruleus in Alzheimer's disease. J Neurol Sci 1986, 76:335-345.
49. Pearson R.C., Esiri M.M., Hiorns R.W., et al. Anatomical correlates of the distribution of the pathological changes in the neocortex in Alzheimer disease. Proc Natl Acad Sci USA 1985, 82:4531-4534.
50. Blessed G., Tomlinson B.E., Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968, 114:797-811.
51. Mann D.M., Marcyniuk B., Yates P.O., et al. The progression of the pathological changes of Alzheimer's disease in frontal and temporal neocortex examined both at biopsy and at autopsy. Neuropathol Appl Neurobiol 1988, 14:177-195.
52. Bennett D.A., Cochran E.J., Saper C.B., et al. Pathological changes in frontal cortex from biopsy to autopsy in Alzheimer's disease. Neurobiol Aging 1993, 14:589-596.
53. Masliah E., Terry R.D., DeTeresa R.M., et al. Immunohistochemical quantification of the synapse-related protein synaptophysin in Alzheimer disease. Neurosci Lett 1989, 103:234-239.
54. Masliah E., Terry R.D., Alford M., et al. Quantitative immunohistochemistry of synaptophysin in human neocortex: an alternative method to estimate density of presynaptic terminals in paraffin sections. J Histochem Cytochem 1990, 38:837-844.
55. Suzuki K., Terry R.D. Fine structural localization of acid phosphatase in senile plaques in Alzheimer's presenile dementia. Acta Neuropathol 1967, 8:276-284.
56. Praprotnik D., Smith M.A., Richey P.L., et al. Filament heterogeneity within the dystrophic neurites of senile plaques suggests blockage of fast axonal transport in Alzheimer's disease. Acta Neuropathol 1996, 91:226-235.
57. Smith M.A., Perry G. The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis. J Neuropathol Exp Neurol 1997, 56:217.
58. Perry G., Nunomura A., Hirai K., et al. Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases?. Free Radic Biol Med 2002, 33:1475-1479.
59. Castellani R.J., Honda K., Zhu X., et al. Contribution of redox-active iron and copper to oxidative damage in Alzheimer disease. Ageing Res Rev 2004, 3:319-326.
60. Nunomura A., Castellani R.J., Zhu X., et al. Involvement of oxidative stress in Alzheimer disease. J Neuropathol Exp Neurol 2006, 65:631-641.
61. Bosman G.J., Bartholomeus I.G., de Grip W.J. Alzheimer's disease and cellular aging: membrane-related events as clues to primary mechanisms. Gerontology 1991, 37:95-112.
62. Nitsch R.M., Blusztajn J.K., Pittas A.G., et al. Evidence for a membrane defect in Alzheimer disease brain. Proc Natl Acad Sci USA 1992, 89:1671-1675.
63. Roth G.S., Joseph J.A., Mason R.P. Membrane alterations as causes of impaired signal transduction in Alzheimer's disease and aging. Trends Neurosci 1995, 18:203-206.
64. Tanzi R.E. The synaptic Abeta hypothesis of Alzheimer disease. Nat Neurosci 2005, 8:977-979.
65. Terry R.D., Masliah E., Salmon D.P., et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991, 30:572-580.
66. Arendt T. Synaptic degeneration in Alzheimer's disease. Acta Neuropathol 2009, 118:167-179.
67. Selkoe D.J. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 2008, 192:106-113.
68. Murphy G.M., Eng L.F., Ellis W.G., et al. Antigenic profile of plaques and neurofibrillary tangles in the amygdala in Down's syndrome: a comparison with Alzheimer's disease. Brain Res 1990, 537:102-108.
69. Rifenburg R.P., Perry G. Dystrophic neurites define diffuse as well as core-containing senile plaques in Alzheimer's disease. Neurodegeneration 1995, 4:235-237.
70. Cras P., Kawai M., Lowery D., et al. Senile plaque neurites in Alzheimer disease accumulate amyloid precursor protein. Proc Natl Acad Sci USA 1991, 88:7552-7556.
71. Morris J.C., Storandt M., McKeel D.W., et al. Cerebral amyloid deposition and diffuse plaques in "normal" aging: evidence for presymptomatic and very mild Alzheimer's disease. Neurology 1996, 46:707-719.
72. Perry G., Lipphardt S., Mulvihill P., et al. Amyloid precursor protein in senile plaques of Alzheimer disease. Lancet 1988, 2:746.
73. Divry P. Etude histochimique des plaques seniles. J Belg Neurol Psychiatr 1972;9:649-57.
74. Masters C.L., Simms G., Weinman N.A., et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 1985, 82:4245-4249.
75. Wong C.W., Quaranta V., Glenner G.G. Neuritic plaques and cerebrovascular amyloid in Alzheimer disease are antigenically related. Proc Natl Acad Sci USA 1985, 82:8729-8732.
76. Allsop D., Landon M., Kidd M., et al. Monoclonal antibodies raised against a subsequence of senile plaque core protein react with plaque cores, plaque periphery and cerebrovascular amyloid in Alzheimer's disease. Neurosci Lett 1986, 68:252-256.
77. Ikeda S., Allsop D., Glenner G.G. Morphology and distribution of plaque and related deposits in the brains of Alzheimer's disease and control cases. An immunohistochemical study using amyloid beta-protein antibody. Lab Invest 1989, 60:113-122.
78. Ikeda S., Yanagisawa N., Allsop D., et al. Evidence of amyloid beta-protein immunoreactive early plaque lesions in Down's syndrome brains. Lab Invest 1989, 61:133-137.
79. Kawai M., Cras P., Perry G. Serial reconstruction of beta-protein amyloid plaques: relationship to microvessels and size distribution. Brain Res 1992, 592:278-282.
80. Pro J.D., Smith C.H., Sumi S.M. Presenile Alzheimer disease: amyloid plaques in the cerebellum. Neurology 1980, 30:820-825.
81. Wisniewski H.M., Bancher C., Barcikowska M., et al. Spectrum of morphological appearance of amyloid deposits in Alzheimer's disease. Acta Neuropathol 1989, 78:337-347.
82. Kidd M. Alzheimer's disease-an electron microscopical study. Brain 1964, 87:307-320.
83. Allsop D., Ikeda S., Bruce M., et al. Cerebrovascular amyloid in scrapie-affected sheep reacts with antibodies to prion protein. Neurosci Lett 1988, 92:234-239.
84. Selkoe D.J., Podlisny M.B., Joachim C.L., et al. Beta-amyloid precursor protein of Alzheimer disease occurs as 110 to 135-kilodalton membrane-associated proteins in neural and nonneural tissues. Proc Natl Acad Sci USA 1988, 85:7341-7345.
85. McGeer P.L., Rogers J., McGeer E.G. Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years. J Alzheimers Dis 2006, 9:271-276.
86. Hardy J.A., Mann D.M., Wester P., et al. An integrative hypothesis concerning the pathogenesis and progression of Alzheimer's disease. Neurobiol Aging 1986, 7:489-502.
87. Rudelli R.D., Ambler M.W., Wisniewski H.M. Morphology and distribution of Alzheimer neuritic (senile) and amyloid plaques in striatum and diencephalon. Acta Neuropathol 1984, 64:273-281.
88. Bondareff W., Mountjoy C.Q., Roth M., et al. Age and histopathologic heterogeneity in Alzheimer's disease. Evidence for subtypes. Arch Gen Psychiatry 1987, 44:412-417.
89. Glenner G.G. Congophilic microangiopathy in the pathogenesis of Alzheimer's syndrome (presenile dementia). Med Hypotheses 1979, 5:1231-1236.
90. Miyakawa T., Shimoji A., Kuramoto R., et al. The relationship between senile plaques and cerebral blood vessels in Alzheimer's disease and senile dementia. Morphological mechanism of senile plaque production. Virchows Arch B Cell Pathol Incl Mol Pathol 1982, 40:121-129.
91. Kawai M., Kalaria R.N., Harik S.I., et al. The relationship of amyloid plaques to cerebral capillaries in Alzheimer's disease. Am J Pathol 1990, 137:1435-1446.
92. Probst A., Brunnschweiler H., Lautenschlager C., et al. A special type of senile plaque, possibly an initial stage. Acta Neuropathol 1987, 74:133-141.
93. DiPatre P.L., Gelman B.B. Microglial cell activation in aging and Alzheimer disease: partial linkage with neurofibrillary tangle burden in the hippocampus. J Neuropathol Exp Neurol 1997, 56:143-149.
94. Selkoe D.J., Bell D.S., Podlisny M.B., et al. Conservation of brain amyloid proteins in aged mammals and humans with Alzheimer's disease. Science 1987, 235:873-877.
95. Hansen L.A., Masliah E., Galasko D., et al. Plaque-only Alzheimer disease is usually the Lewy body variant, and vice versa. J Neuropathol Exp Neurol 1993, 52:648-654.
96. Mann D.M., Jones D. Deposition of amyloid (A4) protein within the brains of persons with dementing disorders other than Alzheimer's disease and Down's syndrome. Neurosci Lett 1990, 109:68-75.
97. Kirschner D.A., Abraham C., Selkoe D.J. X-ray diffraction from intraneuronal paired helical filaments and extraneuronal amyloid fibers in Alzheimer disease indicates cross-beta conformation. Proc Natl Acad Sci USA 1986, 83:503-507.
98. Kidd M. Paired helical filaments in electron microscopy of Alzheimer's disease. Nature 1963, 197:192-193.
99. Wisniewski H.M., Narang H.K., Terry R.D. Neurofibrillary tangles of paired helical filaments. J Neurol Sci 1976, 27:173-181.
100. Terry R.D., Gonatas N.K., Weiss M. Ultrastructural Studies in Alzheimer's presenile dementia. Am J Pathol 1964, 44:269-297.
101. Wischik C.M., Crowther R.A., Stewart M., et al. Subunit structure of paired helical filaments in Alzheimer's disease. J Cell Biol 1985, 100:1905-1912.
102. Crowther R.A., Wischik C.M. Image reconstruction of the Alzheimer paired helical filament. EMBO J 1985, 4:3661-3665.
103. Pollanen M.S., Markiewicz P., Bergeron C., et al. Twisted ribbon structure of paired helical filaments revealed by atomic force microscopy. Am J Pathol 1994, 144:869-873.
104. Pollanen M.S., Markiewicz P., Goh M.C. Paired helical filaments are twisted ribbons composed of two parallel and aligned components: image reconstruction and modeling of filament structure using atomic force microscopy. J Neuropathol Exp Neurol 1997, 56:79-85.
105. Perry G., Mulvihill P., Manetto V., et al. Immunocytochemical properties of Alzheimer straight filaments. J Neurosci 1987, 7:3736-3738.
106. Braak H., Braak E., Grundke-Iqbal I., et al. Occurrence of neuropil threads in the senile human brain and in Alzheimer's disease: a third location of paired helical filaments outside of neurofibrillary tangles and neuritic plaques. Neurosci Lett 1986, 65:351-355.
107. Selkoe D.J., Ihara Y., Salazar F.J. Alzheimer's disease: insolubility of partially purified paired helical filaments in sodium dodecyl sulfate and urea. Science 1982, 215:1243-1245.
108. Smith M.A., Siedlak S.L., Richey P.L., et al. Quantitative solubilization and analysis of insoluble paired helical filaments from Alzheimer disease. Brain Res 1996, 717:99-108.
109. Smith M.A. Alzheimer disease. Int Rev Neurobiol 1998, 42:1-54.
110. Kalaria R.N. The immunopathology of Alzheimer's disease and some related disorders. Brain Pathol 1993, 3:333-347.
111. Castellani R.J., Harris P.L., Sayre L.M., et al. Active glycation in neurofibrillary pathology of Alzheimer disease: N(epsilon)-(carboxymethyl) lysine and hexitol-lysine. Free Radic Biol Med 2001, 31:175-180.
112. Castellani R.J., Perry G., Siedlak S.L., et al. Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans. Neurosci Lett 2002, 319:25-28.
113. Klatzo I., Wisniewski H., Streicher E. Experimental production of neurofibrillary degeneration. I. Light microscopic observations. J Neuropathol Exp Neurol 1965, 24:187-199.
114. Burks J.S., Alfrey A.C., Huddlestone J., et al. A fatal encephalopathy in chronic haemodialysis patients. Lancet 1976, 1:764-768.
115. Castellani R.J., Smith M.A., Perry G., et al. Cerebral amyloid angiopathy: major contributor or decorative response to Alzheimer's disease pathogenesis. Neurobiol Aging 2004, 25:599-602. discussion 603-4.
116. Castellani R.J., Siedlak S.L., Fortino A.E., et al. Chitin-like polysaccharides in Alzheimer's disease brains. Curr Alzheimer Res 2005, 2:419-423.
117. Pfeifer L.A., White L.R., Ross G.W., et al. Cerebral amyloid angiopathy and cognitive function: the HAAS autopsy study. Neurology 2002, 58:1629-1634.
118. Natte R., Maat-Schieman M.L., Haan J., et al. Dementia in hereditary cerebral hemorrhage with amyloidosis-Dutch type is associated with cerebral amyloid angiopathy but is independent of plaques and neurofibrillary tangles. Ann Neurol 2001, 50:765-772.
119. Knudsen K.A., Rosand J., Karluk D., et al. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology 2001, 56:537-539.
120. Jellinger K.A., Attems J. Incidence of cerebrovascular lesions in Alzheimer's disease: a postmortem study. Acta Neuropathol 2003, 105:14-17.
121. Ellis R.J., Olichney J.M., Thal L.J., et al. Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience. Part XV. Neurology 1996, 46:1592-1596.
122. Nicoll J.A., Burnett C., Love S., et al. High frequency of apolipoprotein E epsilon 2 allele in hemorrhage due to cerebral amyloid angiopathy. Ann Neurol 1997, 41:716-721.
123. Wilson C.A., Doms R.W., Lee V.M. Intracellular APP processing and A beta production in Alzheimer disease. J Neuropathol Exp Neurol 1999, 58:787-794.
124. Hyman B.T. The neuropathological diagnosis of Alzheimer's disease: clinical-pathological studies. Neurobiol Aging 1997, 18:S27-S32.
125. Giannakopoulos P., Gold G., Duc M., et al. Impaired processing of famous faces in Alzheimer's disease is related to neurofibrillary tangle densities in the prefrontal and anterior cingulate cortex. Dement Geriatr Cogn Disord 2000, 11:336-341.
126. Pfeifer M., Boncristiano S., Bondolfi L., et al. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 2002, 298:1379.
127. Atwood C.S., Bishop G.M., Perry G., et al. Amyloid-beta: a vascular sealant that protects against hemorrhage?. J Neurosci Res 2002, 70:356.
128. Castellani R.J., Lee H.G., Zhu X., et al. Neuropathology of Alzheimer disease: pathognomonic but not pathogenic. Acta Neuropathol 2006, 111:503-509.
129. Perry G., Castellani R.J., Hirai K., et al. Reactive oxygen species mediate cellular damage in Alzheimer disease. J Alzheimers Dis 1998, 1:45-55.
130. Hirano A., Dembitzer H.M., Kurland L.T., et al. The fine structure of some intraganglionic alterations. Neurofibrillary tangles, granulovacuolar bodies and "rod-like" structures as seen in Guam amyotrophic lateral sclerosis and Parkinsonism-dementia complex. J Neuropathol Exp Neurol 1968, 27:167-182.
131. Galloway P.G., Perry G., Gambetti P. Hirano body filaments contain actin and actin-associated proteins. J Neuropathol Exp Neurol 1987, 46:185-199.
132. Lowe J., Blanchard A., Morrell K., et al. Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease, as well as Rosenthal fibres in cerebellar astrocytomas, cytoplasmic bodies in muscle, and Mallory bodies in alcoholic liver disease. J Pathol 1988, 155:9-15.
133. Ii K., Ito H., Tanaka K., et al. Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly. J Neuropathol Exp Neurol 1997, 56:125-131.
134. Price D.L., Altschuler R.J., Struble R.G., et al. Sequestration of tubulin in neurons in Alzheimer's disease. Brain Res 1986, 385:305-310.
135. Anderson P., Kedersha N. Granules: post-transcriptional and epigenetic modulators of gene expression. Nat Rev Mol Cell Biol 2009, 10:430-436.
136. Glenner G.G., Wong C.W. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 1984, 122:1131-1135.
137. Kang J., Lemaire H.G., Unterbeck A., et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987, 325:733-736.
138. Lemaire H.G., Salbaum J.M., Multhaup G., et al. The PreA4(695) precursor protein of Alzheimer's disease A4 amyloid is encoded by 16 exons. Nucleic Acids Res 1989, 17:517-522.
139. Yamada T., Sasaki H., Dohura K., et al. Structure and expression of the alternatively-spliced forms of mRNA for the mouse homolog of Alzheimer's disease amyloid beta protein precursor. Biochem Biophys Res Commun 1989, 158:906-912.
140. Tanzi R.E., McClatchey A.I., Lamperti E.D., et al. Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's disease. Nature 1988, 331:528-530.
141. Weidemann A., Konig G., Bunke D., et al. Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein. Cell 1989, 57:115-126.
142. Kitaguchi N., Takahashi Y., Tokushima Y., et al. Novel precursor of Alzheimer's disease amyloid protein shows protease inhibitory activity. Nature 1988, 331:530-532.
143. Ponte P., Gonzalez-DeWhitt P., Schilling J., et al. A new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibitors. Nature 1988, 331:525-527.
144. Kang J., Muller-Hill B. Differential splicing of Alzheimer's disease amyloid A4 precursor RNA in rat tissues: PreA4(695) mRNA is predominantly produced in rat and human brain. Biochem Biophys Res Commun 1990, 166:1192-1200.
145. Golde T.E., Estus S., Usiak M., et al. Expression of beta amyloid protein precursor mRNAs: recognition of a novel alternatively spliced form and quantitation in Alzheimer's disease using PCR. Neuron 1990, 4:253-267.
146. Hyman B.T., Van Hoesen G.W., Beyreuther K., et al. A4 amyloid protein immunoreactivity is present in Alzheimer's disease neurofibrillary tangles. Neurosci Lett 1989, 101:352-355.
147. Kitamoto T., Ogomori K., Tateishi J., et al. Formic acid pretreatment enhances immunostaining of cerebral and systemic amyloids. Lab Invest 1987, 57:230-236.
148. Yamaguchi H., Nakazato Y., Hirai S., et al. Electron micrograph of diffuse plaques. Initial stage of senile plaque formation in the Alzheimer brain. Am J Pathol 1989, 135:593-597.
149. Allsop D., Landon M., Kidd M. The isolation and amino acid composition of senile plaque core protein. Brain Res 1983, 259:348-352.
150. Dong J., Atwood C.S., Anderson V.E., et al. Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence. Biochemistry 2003, 42:2768-2773.
151. Kidd M., Allsop D., Landon M. Senile plaque amyloid, paired helical filaments, and cerebrovascular amyloid in Alzheimer's disease are all deposits of the same protein. Lancet 1985, 1:278.
152. Perry G., Richey P.L., Siedlak S.L., et al. Immunocytochemical evidence that the beta-protein precursor is an integral component of neurofibrillary tangles of Alzheimer's disease. Am J Pathol 1993, 143:1586-1593.
153. Zagorski M.G., Barrow C.J. NMR studies of amyloid beta-peptides: proton assignments, secondary structure, and mechanism of an alpha-helix-beta-sheet conversion for a homologous, 28-residue, N-terminal fragment. Biochemistry 1992, 31:5621-5631.
154. Hilbich C., Kisters-Woike B., Reed J., et al. Aggregation and secondary structure of synthetic amyloid beta A4 peptides of Alzheimer's disease. J Mol Biol 1991, 218:149-163.
155. Higgins L.S., Murphy G.M., Forno L.S., et al. P3 beta-amyloid peptide has a unique and potentially pathogenic immunohistochemical profile in Alzheimer's disease brain. Am J Pathol 1996, 149:585-596.
156. Pardridge W.M., Vinters H.V., Yang J., et al. Amyloid angiopathy of Alzheimer's disease: amino acid composition and partial sequence of a 4,200-dalton peptide isolated from cortical microvessels. J Neurochem 1987, 49:1394-1401.
157. Selkoe D.J., Abraham C.R., Podlisny M.B., et al. Isolation of low-molecular-weight proteins from amyloid plaque fibers in Alzheimer's disease. J Neurochem 1986, 46:1820-1834.
158. Selkoe D.J. Amyloid beta-protein and the genetics of Alzheimer's disease. J Biol Chem 1996, 271:18295-18298.
159. Selkoe D.J., Yamazaki T., Citron M., et al. The role of APP processing and trafficking pathways in the formation of amyloid beta-protein. Ann NY Acad Sci 1996, 777:57-64.
160. Bacskai B.J., Frosch M.P., Freeman S.H., et al. Molecular imaging with Pittsburgh compound B confirmed at autopsy: a case report. Arch Neurol 2007, 64:431-434.
161. Pike K.E., Savage G., Villemagne V.L., et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007, 130:2837-2844.
162. Jack C.R., Lowe V.J., Senjem M.L., et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008, 131:665-680.
163. Villemagne V.L., Ataka S., Mizuno T., et al. High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch Neurol 2009, 66:1537-1544.
164. Morris J.C., Roe C.M., Grant E.A., et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 2009, 66:1469-1475.
165. Tellez-Nagel I., Wisniewski H.M. Ultrastructure of neurofibrillary tangles in Steele-Richardson-Olszewski syndrome. Arch Neurol 1973, 29:324-327.
166. Grundke-Iqbal I., Iqbal K., Tung Y.C., et al. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 1986, 83:4913-4917.
167. Santacruz K., Lewis J., Spires T., et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005, 309:476-481.
168. Stokin G.B., Lillo C., Falzone T.L., et al. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science 2005, 307:1282-1288.
169. Yoshiyama Y., Higuchi M., Zhang B., et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007, 53:337-351.
170. Lee H.G., Perry G., Moreira P.I., et al. Tau phosphorylation in Alzheimer's disease: pathogen or protector?. Trends Mol Med 2005, 11:164-169.
171. Morsch R., Simon W., Coleman P.D. Neurons may live for decades with neurofibrillary tangles. J Neuropathol Exp Neurol 1999, 58:188-197.
172. Cash A.D., Aliev G., Siedlak S.L., et al. Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation. Am J Pathol 2003, 162:1623-1627.
173. Breitner J.C., Folstein M.F. Familial Alzheimer dementia: a prevalent disorder with specific clinical features. Psychol Med 1984, 14:63-80.
174. Rodgers-Johnson P., Garruto R.M., Yanagihara R., et al. Amyotrophic lateral sclerosis and Parkinsonism-dementia on Guam: a 30-year evaluation of clinical and neuropathologic trends. Neurology 1986, 36:7-13.
175. Schweber M. A possible unitary genetic hypothesis for Alzheimer's disease and Down syndrome. Ann NY Acad Sci 1985, 450:223-238.
176. Selkoe D.J. Alzheimer's disease: genotypes, phenotypes, and treatments. Science 1997, 275:630-631.
177. Hellstrom-Lindahl E., Viitanen M., Marutle A. Comparison of Abeta levels in the brain of familial and sporadic Alzheimer's disease. Neurochem Int 2009, 55:243-252.
178. Sherrington R., Rogaev E.I., Liang Y., et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995, 375:754-760.
179. Namba Y., Tomonaga M., Kawasaki H., et al. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res 1991, 541:163-166.
180. Wisniewski T., Frangione B. Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett 1992, 135:235-238.
181. Strittmatter W.J., Saunders A.M., Schmechel D., et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993, 90:1977-1981.
182. Whitson J.S., Mims M.P., Strittmatter W.J., et al. Attenuation of the neurotoxic effect of A beta amyloid peptide by apolipoprotein E. Biochem Biophys Res Commun 1994, 199:163-170.
183. Gupta S., Rifici V., Crowley S., et al. Interactions of LDL and modified LDL with mesangial cells and matrix. Kidney Int 1992, 41:1161-1169.
184. Tanzi R.E., Kovacs D.M., Kim T.W., et al. The gene defects responsible for familial Alzheimer's disease. Neurobiol Dis 1996, 3:159-168.
185. Harold D., Abraham R., Hollingworth P., et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009, 41:1088-1093.
186. Holtzman D.M. In vivo effects of ApoE and clusterin on amyloid-beta metabolism and neuropathology. J Mol Neurosci 2004, 23:247-254.
187. Berchtold N.C., Cotman C.W. Evolution in the conceptualization of dementia and Alzheimer's disease: Greco-Roman period to the 1960s. Neurobiol Aging 1998, 19:173-189.
188. Katzman R. Education and the prevalence of dementia and Alzheimer's disease. Neurology 1993, 43:13-20.
189. Beard C.M., Kokmen E., Offord K.P., et al. Lack of association between Alzheimer's disease and education, occupation, marital status, or living arrangement. Neurology 1992, 42:2063-2068.
190. Bonaiuto S., Rocca W.A., Lippi A., et al. Education and occupation as risk factors for dementia: a population-based case-control study. Neuroepidemiology 1995, 14:101-109.
191. Butler S.M., Ashford J.W., Snowdon D.A. Age, education, and changes in the mini-mental state exam scores of older women: findings from the Nun Study. J Am Geriatr Soc 1996, 44:675-681.
192. Snowdon D.A., Kemper S.J., Mortimer J.A., et al. Linguistic ability in early life and cognitive function and Alzheimer's disease in late life. Findings from the Nun Study. JAMA 1996, 275:528-532.
193. Jenkinson M.L., Bliss M.R., Brain A.T., et al. Rheumatoid arthritis and senile dementia of the Alzheimer's type. Br J Rheumatol 1989, 28:86-88.
194. Rich J.B., Rasmusson D.X., Folstein M.F., et al. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 1995, 45:51-55.
195. Graves A.B., White E., Koepsell T.D., et al. The association between head trauma and Alzheimer's disease. Am J Epidemiol 1990, 131:491-501.
196. McKee A.C., Cantu R.C., Nowinski C.J., et al. Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. J Neuropathol Exp Neurol 2009, 68:709-735.
197. Franz G., Beer R., Kampfl A., et al. Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury. Neurology 2003, 60:1457-1461.
198. Whitehouse P.J., Price D.L., Struble R.G., et al. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982, 215:1237-1239.
199. Whitehouse P.J. Quality of life: the bridge from the cholinergic basal forebrain to cognitive science and bioethics. J Alzheimers Dis 2006, 9:447-453.
200. Farlow M.R., Evans R.M. Pharmacologic treatment of cognition in Alzheimer's dementia. Neurology 1998, 51:S36-S44. discussion, S65-7.
201. Hebert L.E., Scherr P.A., Bienias J.L., et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003, 60:1119-1122.
202. Giacobini E. Cholinesterase inhibitors stabilize Alzheimer's disease. Ann NY Acad Sci 2000, 920:321-327.
203. Giacobini E. Do cholinesterase inhibitors have disease-modifying effects in Alzheimer's disease?. CNS Drugs 2001, 15:85-91.
204. Giacobini E. Long-term stabilizing effect of cholinesterase inhibitors in the therapy of Alzheimer' disease. J Neural Transm Suppl 2002, 62:181-187.
205. Giacobini E., Mori F., Lai C.C. The effect of cholinesterase inhibitors on the secretion of APPS from rat brain cortex. Ann NY Acad Sci 1996, 777:393-398.
206. Mori F., Lai C.C., Fusi F., et al. Cholinesterase inhibitors increase secretion of APPs in rat brain cortex. Neuroreport 1995, 6:633-636.
207. Summers W.K. Tacrine, and Alzheimer's treatments. J Alzheimers Dis 2006, 9:439-445.
208. Knapp M.J., Knopman D.S., Solomon P.R., et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA 1994, 271:985-991.
209. Whitehouse P.J. Cholinergic therapy in dementia. Acta Neurol Scand Suppl 1993, 149:42-45.
210. Trinh N.H., Hoblyn J., Mohanty S., et al. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 2003, 289:210-216.
211. Mulugeta E., Karlsson E., Islam A., et al. Loss of muscarinic M4 receptors in hippocampus of Alzheimer patients. Brain Res 2003, 960:259-262.
212. Winblad B., Grossberg G., Frolich L., et al. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 2007, 69:S14-S22.
213. Kamal M.A., Klein P., Yu Q.S., et al. Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine. J Alzheimers Dis 2006, 10:43-51.
214. Fischer W., Wictorin K., Bjorklund A., et al. Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature 1987, 329:65-68.
215. Hefti F. Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transections. J Neurosci 1986, 6:2155-2162.
216. Kromer L.F. Nerve growth factor treatment after brain injury prevents neuronal death. Science 1987, 235:214-216.
217. Williams L.R., Varon S., Peterson G.M., et al. Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transection. Proc Natl Acad Sci USA 1986, 83:9231-9235.
218. Cooper J.D., Salehi A., Delcroix J.D., et al. Failed retrograde transport of NGF in a mouse model of Down's syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion. Proc Natl Acad Sci USA 2001, 98:10439-10444.
219. Holtzman D.M., Li Y., Chen K., et al. Nerve growth factor reverses neuronal atrophy in a Down syndrome model of age-related neurodegeneration. Neurology 1993, 43:2668-2673.
220. Markowska A.L., Koliatsos V.E., Breckler S.J., et al. Human nerve growth factor improves spatial memory in aged but not in young rats. J Neurosci 1994, 14:4815-4824.
221. Tuszynski M.H., Gage F.H. Bridging grafts and transient nerve growth factor infusions promote long-term central nervous system neuronal rescue and partial functional recovery. Proc Natl Acad Sci USA 1995, 92:4621-4625.
222. Emerich D.F., Winn S.R., Harper J., et al. Implants of polymer-encapsulated human NGF-secreting cells in the nonhuman primate: rescue and sprouting of degenerating cholinergic basal forebrain neurons. J Comp Neurol 1994, 349:148-164.
223. Koliatsos V.E., Clatterbuck R.E., Nauta H.J., et al. Human nerve growth factor prevents degeneration of basal forebrain cholinergic neurons in primates. Ann Neurol 1991, 30:831-840.
224. Kordower J.H., Winn S.R., Liu Y.T., et al. The aged monkey basal forebrain: rescue and sprouting of axotomized basal forebrain neurons after grafts of encapsulated cells secreting human nerve growth factor. Proc Natl Acad Sci USA 1994, 91:10898-10902.
225. Tuszynski M.H., U H.S., Amaral D.G., et al. Nerve growth factor infusion in the primate brain reduces lesion-induced cholinergic neuronal degeneration. J Neurosci 1990, 10:3604-3614.
226. Tuszynski M.H., Sang H., Yoshida K., et al. Recombinant human nerve growth factor infusions prevent cholinergic neuronal degeneration in the adult primate brain. Ann Neurol 1991, 30:625-636.
227. Tuszynski M.H., Roberts J., Senut M.C., et al. Gene therapy in the adult primate brain: intraparenchymal grafts of cells genetically modified to produce nerve growth factor prevent cholinergic neuronal degeneration. Gene Ther 1996, 3:305-314.
228. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology 1996, 46:1244-1249. Als CNTF, Treatment Study Group.
229. A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III). Neurology 1999, 52:1427-1433.
230. Eriksdotter Jonhagen M., Nordberg A., Amberla K., et al. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord 1998, 9:246-257.
231. Kordower J.H., Palfi S., Chen E.Y., et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 1999, 46:419-424.
232. Chen K.S., Gage F.H. Somatic gene transfer of NGF to the aged brain: behavioral and morphological amelioration. J Neurosci 1995, 15:2819-2825.
233. Conner J.M., Darracq M.A., Roberts J., et al. Actions of neurotrophins: subcortical nerve growth factor gene delivery reverses age-related degeneration of primate cortical cholinergic innervation. Proc Natl Acad Sci USA 2001, 98:1941-1946.
234. Rosenberg M.B., Friedmann T., Robertson R.C., et al. Grafting genetically modified cells to the damaged brain: restorative effects of NGF expression. Science 1988, 242:1575-1578.
235. Smith D.E., Roberts J., Gage F.H., et al. Age-associated neuronal atrophy occurs in the primate brain and is reversible by growth factor gene therapy. Proc Natl Acad Sci USA 1999, 96:10893-10898.
236. Tuszynski M.H., Thal L., Pay M., et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005, 11:551-555.
237. Alexander G.E., Chen K., Pietrini P., et al. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry 2002, 159:738-745.
238. Blesch A., Conner J., Pfeifer A., et al. Regulated lentiviral NGF gene transfer controls rescue of medial septal cholinergic neurons. Mol Ther 2005, 11:916-925.
239. Klein R.L., Hirko A.C., Meyers C.A., et al. Transfer to intrinsic basal forebrain neurons increases cholinergic cell size and protects from age-related, spatial memory deficits in middle-aged rats. Brain Res 2000, 875:144-151.
240. Tuszynski M.H. Nerve growth factor gene therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 2007, 21:179-189.
241. Nunomura A., Perry G., Pappolla M.A., et al. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J Neurosci 1999, 19:1959-1964.
242. Nunomura A., Perry G., Aliev G., et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 2001, 60:759-767.
243. Sayre L.M., Zelasko D.A., Harris P.L., et al. Four-hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem 1997, 68:2092-2097.
244. Jama J.W., Launer L.J., Witteman J.C., et al. Dietary antioxidants and cognitive function in a population-based sample of older persons. The Rotterdam Study. Am J Epidemiol 1996, 144:275-280.
245. Perrig W.J., Perrig P., Stahelin H.B. The relation between antioxidants and memory performance in the old and very old. J Am Geriatr Soc 1997, 45:718-724.
246. Rottkamp C.A., Nunomura A., Hirai K., et al. Will antioxidants fulfill their expectations for the treatment of Alzheimer disease?. Mech Ageing Dev 2000, 116:169-179.
247. Sano M., Ernesto C., Thomas R.G., et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's disease Cooperative Study. N Engl J Med 1997, 336:1216-1222.
248. Zandi P.P., Anthony J.C., Khachaturian A.S., et al. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol 2004, 61:82-88.
249. Fassbender K., Simons M., Bergmann C., et al. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA 2001, 98:5856-5861.
250. Li G., Larson E.B., Sonnen J.A., et al. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology 2007, 69:878-885.
251. Li G., Higdon R., Kukull W.A., et al. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology 2004, 63:1624-1628.
252. Li G., Kukull W.A., Peskind E., et al. Differential effect of statins on risk of AD by age, sex and APOE genotype: findings from a community-based prospective cohort study. Alzheimer Dis Assoc Disord 2006, 20:S103-S104.
253. Jick H., Zornberg G.L., Jick S.S., et al. Statins and the risk of dementia. Lancet 2000, 356:1627-1631.
254. Rockwood K., Kirkland S., Hogan D.B., et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 2002, 59:223-227.
255. Wolozin B., Kellman W., Ruosseau P., et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000, 57:1439-1443.
256. Yaffe K., Barrett-Connor E., Lin F., et al. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 2002, 59:378-384.
257. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22.
258. Rea T.D., Breitner J.C., Psaty B.M., et al. Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch Neurol 2005, 62:1047-1051.
259. Shepherd J., Blauw G.J., Murphy M.B., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002, 360:1623-1630.
260. Zandi P.P., Sparks D.L., Khachaturian A.S., et al. Do statins reduce risk of incident dementia and Alzheimer disease?. The Cache County Study. Arch Gen Psychiatry 2005, 62:217-224.
261. Rogers J., Cooper N.R., Webster S., et al. Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci USA 1992, 89:10016-10020.
262. Dickson D.W., Lee S.C., Mattiace L.A., et al. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia 1993, 7:75-83.
263. Griffin W.S., Stanley L.C., Ling C., et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 1989, 86:7611-7615.
264. Breitner J.C., Gau B.A., Welsh K.A., et al. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology 1994, 44:227-232.
265. Stewart W.F., Kawas C., Corrada M., et al. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997, 48:626-632.
266. Andersen K., Launer L.J., Ott A., et al. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease?. The Rotterdam Study. Neurology 1995, 45:1441-1445.
267. Rogers J., Kirby L.C., Hempelman S.R., et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993, 43:1609-1611.
268. Aisen P.S., Schafer K.A., Grundman M., et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003, 289:2819-2826.
269. Thal L.J., Ferris S.H., Kirby L., et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 2005, 30:1204-1215.
270. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response?. Nat Med 2006, 12:1005-1015.
271. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's disease anti-inflammatory Prevention Trial (ADAPT). PLoS. Clin Trials 2006, 1:e33.
272. Goutte C., Tsunozaki M., Hale V.A., et al. APH-1 is a multipass membrane protein essential for the notch signaling pathway in Caenorhabditis elegans embryos. Proc Natl Acad Sci USA 2002, 99:775-779.
273. Bard F., Cannon C., Barbour R., et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000, 6:916-919.
274. Janus C., Pearson J., McLaurin J., et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000, 408:979-982.
275. Morgan D., Diamond D.M., Gottschall P.E., et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000, 408:982-985.
276. Mucke L., Masliah E., Yu G.Q., et al. High-level neuronal expression of Abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 2000, 20:4050-4058.
277. Nicoll J.A., Wilkinson D., Holmes C., et al. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003, 9:448-452.
278. Becher B., Prat A., Antel J.P. Brain-immune connection: immuno-regulatory properties of CNS-resident cells. Glia 2000, 29:293-304.
279. Francis R., McGrath G., Zhang J., et al. aph-1 and pen-2 are required for notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. Dev Cell 2002, 3:85-97.
280. Monsonego A., Zota V., Karni A., et al. Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest 2003, 112:415-422.
281. Casadesus G., Milliken E.L., Webber K.M., et al. Increases in luteinizing hormone are associated with declines in cognitive performance. Mol Cell Endocrinol 2007, 269:107-111.
282. Webber K.M., Casadesus G., Marlatt M.W., et al. Estrogen bows to a new master: the role of gonadotropins in Alzheimer pathogenesis. Ann NY Acad Sci 2005, 1052:201-209.
283. Kornhuber J., Bormann J., Retz W., et al. Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur J Pharmacol 1989, 166:589-590.
284. Misztal M., Frankiewicz T., Parsons C.G., et al. Learning deficits induced by chronic intraventricular infusion of quinolinic acid-protection by MK-801 and memantine. Eur J Pharmacol 1996, 296:1-8.
285. Wenk G.L., Danysz W., Roice D.D. The effects of mitochondrial failure upon cholinergic toxicity in the nucleus basalis. Neuroreport 1996, 7:1453-1456.
286. Zajaczkowski W., Quack G., Danysz W. Infusion of (+) -MK-801 and memantine-contrasting effects on radial maze learning in rats with entorhinal cortex lesion. Eur J Pharmacol 1996, 296:239-246.
287. Reisberg B., Doody R., Stoffler A., et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003, 348:1333-1341.
288. van Dyck C.H., Tariot P.N., Meyers B., et al. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord 2007, 21:136-143.
289. McShane R., Areosa Sastre A., Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006, CD003154.
290. Tariot P.N., Farlow M.R., Grossberg G.T., et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004, 291:317-324.
291. Scarmeas N., Stern Y., Tang M.X., et al. Mediterranean diet and risk for Alzheimer's disease. Ann Neurol 2006, 59:912-921.
292. Schenk D., Barbour R., Dunn W., et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
293. Nicoll J.A., Barton E., Boche D., et al. Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol 2006, 65:1040-1048.
294. Orgogozo J.M., Gilman S., Dartigues J.F., et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003, 61:46-54.
295. Gilman S., Koller M., Black R.S., et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64:1553-1562.
296. Kim H.D., Tahara K., Maxwell J.A., et al. Nasal inoculation of an adenovirus vector encoding 11 tandem repeats of Abeta1-6 upregulates IL-10 expression and reduces amyloid load in a Mo/Hu APPswe PS1dE9 mouse model of Alzheimer's disease. J Gene Med 2007, 9:88-98.
297. Nikolic W.V., Bai Y., Obregon D., et al. Transcutaneous beta-amyloid immunization reduces cerebral beta-amyloid deposits without T cell infiltration and microhemorrhage. Proc Natl Acad Sci USA 2007, 104:2507-2512.
298. Asuni A.A., Boutajangout A., Scholtzova H., et al. Vaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhages. Eur J Neurosci 2006, 24:2530-2542.
299. Solomon B. Intravenous immunoglobulin and Alzheimer's disease immunotherapy. Curr Opin Mol Ther 2007, 9:79-85.
300. Chang W.P., Downs D., Huang X.P., et al. Amyloid-beta reduction by memapsin 2 (beta-secretase) immunization. FASEB J 2007, 21:3184-3196.
301. Christensen D.D. Changing the course of Alzheimer's disease: anti-amyloid disease-modifying treatments on the horizon. Prim Care Companion J Clin Psychiatry 2007, 9:32-41.